Forty Seven

General Information


We are a clinical-stage immuno-oncology company focused on developing novel checkpoint therapies to activate macrophages in the fight against cancer. We founded Forty Seven based on the insight that blocking CD47, a key signaling molecule that is overexpressed on cancer cells, renders tumors susceptible to macrophages. By harnessing macrophages, we believe that our lead product candidate, 5F9, dosed as a monotherapy or in combination with marketed cancer therapies, can transform the treatment of cancer. 5F9 has demonstrated promising activity in six Phase 1b/2 clinical trials in which we have treated over 190 relapsed or refractory cancer patients with solid or hematologic tumors. We hold worldwide rights to all of our product candidates.


Employees: 46
Founded: 2014
Contact Information
Address 1490 O’Brien Drive, Suite A, Menlo Park, CA 94025, US
Phone Number (650) 352-4150.
Web Address
View Prospectus: Forty Seven
Financial Information
Market Cap $479.4mil
Revenues $0 mil (last 12 months)
Net Income $-48.8 mil (last 12 months)
IPO Profile
Symbol FTSV
Exchange NASDAQ
Shares (millions): 7.0
Price range $16.00 - $16.00
Est. $ Volume $112.6 mil
Manager / Joint Managers Morgan Stanley/ Credit Suisse
CO-Managers Canaccord Genuity/ BTIG/ Oppenheimer
Expected To Trade: 6/28/2018
Status: Priced
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change